Microbix Biosystems (TSX:MBX) Research & Development: C$2.38 Mil (TTM As of Mar. 2026)


TSX:MBX Microbix Biosystems Inc TSX:MBX
52 GF Score
Price C$0.31
GF Value C$0.24
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Research & Development?

Microbix Biosystems TSX:MBX +5.17% 52 Research & Development is C$2.38 Mil as of Mar. 2026. GuruFocus rates TSX:MBX with a GF Score™ of 52/100 and a GF Value™ of C$0.24 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Microbix Biosystems's Research & Development for the three months ended in Mar. 2026 was C$0.60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$2.38 Mil.

Microbix Biosystems  (TSX:MBX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Microbix Biosystems Research & Development Related Terms

Microbix Biosystems Research & Development Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems Research & Development Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 1.80 2.05 2.13 2.33

Microbix Biosystems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.59 0.63 0.56 0.60
TSX:MBX
52GF Score
Microbix Biosystems Inc TSX:MBX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$2.38 Mil mean?
Microbix Biosystems (TSX:MBX) has a Research & Development of C$2.38 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Research & Development too high?
Microbix Biosystems' current Research & Development is C$2.38 Mil. Overall, Microbix Biosystems has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Research & Development compare to VRTX and REGN?
Microbix Biosystems' Research & Development of C$2.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Research & Development is C$2.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.24, compared to a current price of C$0.31 — trading 27.1% above its estimated fair value. The current Research & Development is C$2.38 Mil. Microbix Biosystems' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current Research & Development is C$2.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of C$0.31 is trading 27.1% above its estimated GF Value™ of C$0.24. GuruFocus considers Microbix Biosystems to be Modestly Overvalued.

Key valuation signals for TSX:MBX:

  • Research & Development: C$2.38 Mil
  • GF Value™: C$0.24 vs. price of C$0.31 (27.1% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Other Exchanges MBXBF:USA
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
52GF Score

Get the complete analysis for TSX:MBX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.31
Price
C$0.24
GF Value